X

XORTX Therapeutics
D

XRTX

0.85000
USD
-0.10
(-10.05%)
مغلق
حجم التداول
3,460
الربح لكل سهم
-2
العائد الربحي
-
P/E
7
حجم السوق
2,740,030
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABT
    ABT
    1.785
    (1.34%)
    134.950 USD
    BDX
    BDX
    -0.590
    (-0.26%)
    227.450 USD
    H
    HOLX
    0.180
    (0.28%)
    64.510 USD
    IDXX
    IDXX
    -0.33
    (-0.07%)
    452.66 USD
    ISRG
    ISRG
    -15.37
    (-2.53%)
    591.50 USD
    R
    RGEN
    -3.710
    (-2.28%)
    158.950 USD
    RMD
    RMD
    -1.320
    (-0.57%)
    231.520 USD
    T
    TECH
    -0.510
    (-0.78%)
    64.920 USD
    TMO
    TMO
    -5.71
    (-1.06%)
    532.28 USD
    المزيد
الأخبار
المقالات

العنوان: XORTX Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.